ProNAi Therapeutics (DNAI) IPO Opens Up 69%

Go back to ProNAi Therapeutics (DNAI) IPO Opens Up 69%

ProNAi Therapeutics (DNAI) Prices 8.1M Common Stock IPO at $17/Share

July 16, 2015 10:13 AM EDT

ProNAi Therapeutics, Inc. (Nasdaq: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced the pricing of its initial public offering of 8,100,000 shares of its common stock at a price to the public of... More

IPOs for July 16th

July 15, 2015 3:58 PM EDT

Expected IPOs for July 16th:

Innovation Economy (Nasdaq: MYIE - will offer 3.125 million shares and sees an offering price of $6.40 per shareProNAi Therapeutics, Inc. (Nasdaq: DNAI) - will offer 8.1 million shares and sees an offering price of $14.00 - $16.00 per... More

ProNAi Therapeutics (DNAI) Sees IPO Pricing of ~$17/Share, Above Previous Range

July 15, 2015 2:22 PM EDT

ProNAi Therapeutics, Inc. (Nasdaq: DNAI) filed a amended registration with the U.S. SEC for an IPO of its Common Stock. The company plans to sell 8.1 million shares and sees an offering price of about $17 per share. Previously, the company was planning to offer 6.7 million shares with an expected offering price of $14 to $16 per share. The company will trade on the Nasdaq Global Market under the ticker, "DNAI."

Underwriters are Jefferies, BofA Merrill Lynch, Wedbush PacGrow, and SunTrust Robinson Humphrey.

ProNAi Therapeutics... More